Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 104

    1.

    A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK.

    Moore L, Remy V, Martin M, Beillat M, McGuire A.

    Cost Eff Resour Alloc. 2010 Apr 30;8:7.

    PMID:
    20433704
    [PubMed]
    Free PMC Article
    2.

    Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.

    Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel JP, Fendl A, Bresse X.

    Hum Vaccin. 2011 Jul;7(7):749-56. Epub 2011 Jul 1.

    PMID:
    21606685
    [PubMed - in process]
    Free PMC Article
    3.

    The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.

    Brisson M, Pellissier JM, Camden S, Quach C, De Wals P.

    Hum Vaccin. 2008 May-Jun;4(3):238-45. Epub 2010 May 25.

    PMID:
    18382137
    [PubMed - indexed for MEDLINE]
    Free Article
    4.

    Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

    Pellissier JM, Brisson M, Levin MJ.

    Vaccine. 2007 Nov 28;25(49):8326-37. Epub 2007 Oct 17.

    PMID:
    17980938
    [PubMed - indexed for MEDLINE]
    5.

    Cost effectiveness of herpes zoster vaccine in Canada.

    Najafzadeh M, Marra CA, Galanis E, Patrick DM.

    Pharmacoeconomics. 2009;27(12):991-1004. doi: 10.2165/11314010-000000000-00000.

    PMID:
    19908924
    [PubMed - indexed for MEDLINE]
    6.

    Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

    Hornberger J, Robertus K.

    Ann Intern Med. 2006 Sep 5;145(5):317-25.

    PMID:
    16954357
    [PubMed - indexed for MEDLINE]
    7.
    8.

    Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.

    Johnson RW.

    Aging Clin Exp Res. 2009 Jun;21(3):236-43. Review.

    PMID:
    19571648
    [PubMed - indexed for MEDLINE]
    9.

    Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

    Shepherd J, Jones J, Takeda A, Davidson P, Price A.

    Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

    PMID:
    16904047
    [PubMed - indexed for MEDLINE]
    Free Article
    10.

    Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

    Rothberg MB, Virapongse A, Smith KJ.

    Clin Infect Dis. 2007 May 15;44(10):1280-8. Epub 2007 Apr 3.

    PMID:
    17443464
    [PubMed - indexed for MEDLINE]
    Free Article
    11.

    Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales.

    van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ.

    Vaccine. 2009 Feb 25;27(9):1454-67. Epub 2009 Jan 9.

    PMID:
    19135492
    [PubMed - indexed for MEDLINE]
    12.

    Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality.

    Brisson M.

    Can J Public Health. 2008 Sep-Oct;99(5):383-6.

    PMID:
    19009921
    [PubMed - indexed for MEDLINE]
    13.

    The impact of herpes zoster and post-herpetic neuralgia on quality-of-life.

    Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T.

    BMC Med. 2010 Jun 21;8:37.

    PMID:
    20565946
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    14.

    Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.

    Ritchie M, Liedgens H, Nuijten M.

    Clin Drug Investig. 2010;30(2):71-87. doi: 10.2165/11533310-000000000-00000.

    PMID:
    20067326
    [PubMed - indexed for MEDLINE]
    15.

    Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study.

    Gialloreti LE, Merito M, Pezzotti P, Naldi L, Gatti A, Beillat M, Serradell L, di Marzo R, Volpi A.

    BMC Infect Dis. 2010 Aug 3;10:230.

    PMID:
    20682044
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    16.

    Community and patient values for preventing herpes zoster.

    Lieu TA, Ortega-Sanchez I, Ray GT, Rusinak D, Yih WK, Choo PW, Shui I, Kleinman K, Harpaz R, Prosser LA.

    Pharmacoeconomics. 2008;26(3):235-49.

    PMID:
    18282017
    [PubMed - indexed for MEDLINE]
    17.

    Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom.

    Gauthier A, Breuer J, Carrington D, Martin M, Rémy V.

    Epidemiol Infect. 2009 Jan;137(1):38-47. Epub 2008 May 9.

    PMID:
    18466661
    [PubMed - indexed for MEDLINE]
    18.

    Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium.

    Bilcke J, Marais C, Ogunjimi B, Willem L, Hens N, Beutels P.

    Vaccine. 2012 Jan 11;30(3):675-84. Epub 2011 Nov 24.

    PMID:
    22120193
    [PubMed - in process]
    19.

    Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.

    Annemans L, Rémy V, Oyee J, Largeron N.

    Pharmacoeconomics. 2009;27(3):231-45. doi: 10.2165/00019053-200927030-00006.

    PMID:
    19354343
    [PubMed - indexed for MEDLINE]
    20.

    The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.

    Connock M, Burls A, Frew E, Fry-Smith A, Juarez-Garcia A, McCabe C, Wailoo A, Abrams K, Cooper N, Sutton A, O'Hagan A, Moore D.

    Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. Review.

    PMID:
    16796930
    [PubMed - indexed for MEDLINE]
    Free Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk